or
forgot password
  • cancer clinical trials in farmington, CT

  • S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Melanoma (Skin)
    Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Melanoma (Skin)
    Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
    University of Connecticut School of Medicine
    Farmington, Connecticut 06032
    Head and Neck Cancer
    Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
    Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia, Myelodysplastic Syndromes, Sarcoma
    Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Cancer
    Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma
    University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Sarcoma
    Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Breast Cancer
    STI571 in Treating Patients With Recurrent Leukemia
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Leukemia
    Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Brain and Central Nervous System Tumors
    Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Leukemia
    Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Leukemia
    Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
    Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Cancer
    DNA Variations in the Gene in Young Patients With Wilms' Tumor
    University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Kidney Cancer
    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia
    Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    University of Connecticut
    Farmington, Connecticut 06032
    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer
    Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia
    Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Breast Cancer
    Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Breast Cancer
    Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Prospective Observational Epidemiologic Study of Maraviroc's Safety
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Human Immunodeficiency Virus
    Cox-2 Inhibition in Radiation-induced Oral Mucositis
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Oral Mucositis
    Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Advanced Breast Cancer, Breast Cancer
    Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Endometrial Cancer, Fatigue, Neurotoxicity
    Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Breast Cancer
    Optical Tomography With Ultrasound Guidance
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Cancer
    Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Breast Cancer, Advanced Breast Cancer
    Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Prostate Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Stage IV Prostate Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
    Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
    University of CT Health Center
    Farmington, Connecticut 06030
    Cancer
    S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Lung Cancer
    Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Endometrial Papillary Serous Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Papillary Serous Carcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Adenoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Adenoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Adenoma, Pancreatic G-cell Carcinoma, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Adult Primary Liver Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Regional Gastrointestinal Carcinoid Tumor, Stage IIIA Endometrial Carcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Endometrial Carcinoma, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Endometrial Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer, Stage IVA Endometrial Carcinoma, Stage IVB Endometrial Carcinoma, Uterine Carcinosarcoma
    Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Colorectal Cancer, Precancerous Condition
    A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Breast Cancer
    Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
    Fulvestrant With or Without Bortezomib in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Estrogen Receptor-positive Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
    Women's Health Specialty Care
    Farmington, Connecticut 06032
    Overactive Bladder
    A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    University of Connecticut Health Center - John Dempsey Hospital/Neag Comprehensive Cancer Center
    Farmington, Connecticut 06034
    Advanced Prostate Cancer, Prostatic Neoplasms
    Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
    Neag Comprehensive Cancer Center/University of Connecticut Health Center
    Farmington, Connecticut 06030
    Urothelial Carcinoma
    ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Non-Small Cell Lung Cancer (NSCLC)
    Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Endometrial Cancer
    Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
    University of Connecticut
    Farmington, Connecticut 06032
    Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Ovarian Neoplasms
    Omega 3 FA Supplements as Augmentation in the Treatment of Depression
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Major Depression, Cancer, Diabetes, Cardiovascular Diseases
    A Lifestyle Intervention for Breast Cancer Survivors
    University of Connecticut
    Farmington, Connecticut 06032
    Breast Cancer
    Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation
    UCHC Division of Reproductive Endocrinology
    Farmington, Connecticut 06030
    Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
    Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia
    Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Kidney Cancer
    Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Kidney Cancer
    Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Cancer
    Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia
    Marimastat in Treating Patients With Stage III Non-Small Cell Lung Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Lung Cancer
    Combination Chemotherapy in Treating Children With Progressive Brain Tumors
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain and Central Nervous System Tumors
    Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
    University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Sarcoma
    Combination Chemotherapy in Treating Children With Neuroblastoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Neuroblastoma
    Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain and Central Nervous System Tumors
    Surgery in Treating Children With Neuroblastoma
    University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Neuroblastoma
    Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
    Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Leukemia
    Vinorelbine in Treating Children With Recurrent or Refractory Cancers
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
    Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
    University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Colorectal Cancer
    Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Sarcoma
    Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
    University of Connecticut Cancer Center at University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Cancer
    Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
    University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Cancer